TY - JOUR
T1 - Testosterone Therapy and Its Monitoring in Adolescent Boys with Hypogonadism
T2 - Results of an International Survey from the I-DSD Registry
AU - Stancampiano, Marianna R
AU - Lucas-Herald, Angela K
AU - Bryce, Jillian
AU - Russo, Gianni
AU - Barera, Graziano
AU - Balsamo, Antonio
AU - Baronio, Federico
AU - Bertelloni, Silvano
AU - Valiani, Margherita
AU - Cools, Martine
AU - Tack, Lloyd J W
AU - Darendeliler, Feyza
AU - Poyrazoglu, Sukran
AU - Globa, Evgenia
AU - Grinspon, Romina
AU - Hannema, Sabine E
AU - Hughes, Ieuan A
AU - Tadokoro-Cuccaro, Rieko
AU - Thankamony, Ajay
AU - Iotova, Violeta
AU - Mladenov, Vilhelm
AU - Konrad, Daniel
AU - Mazen, Inas
AU - Niedziela, Marek
AU - Kolesinska, Zofia
AU - Nordenström, Anna
AU - Ahmed, S Faisal
N1 - Funding Information: The I-DSD Registry was developed using support from an unrestricted education grant from Diurnal Ltd and research grants from the Medical Research Council (G1100236), the Seventh European Union Framework Program (201444), and the European Society for Paediatric Endocrinology Research Unit. Publisher Copyright: © 2021 The Author(s) Published by S. Karger AG, Basel. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - It is unclear whether testosterone replacement therapy (TRT) in adolescent boys, affected by a range of endocrine diseases that may be associated with hypogonadism, is particularly common. The aim of this study was to assess the contemporary practice of TRT in boys included in the I-DSD Registry. All participating centres in the I-DSD Registry that had boys between 10 and 18 years of age and with a condition that could be associated with hypogonadism were invited to provide further information in 2019. Information on 162 boys was collected from 15 centres that had a median (range) number of 6 boys per centre (1.35). Of these, 30 (19%) from 9 centres were receiving TRT and the median (range) age at the start was 12.6 years (10.8-16.2), with 6 boys (20%) starting at <12 years. Median (range) age of boys not on TRT was 11.7 years (10.7-17.7), and 69 out of 132 (52%) were <12 years. TRT had been initiated in 20 of 71 (28%) boys with a disorder of gonadal development, 3 of 14 (21%) with a disorder of androgen synthesis, and all 7 (100%) boys with hypogonadotropic hypogonadism. The remainder who did not have TRT included 15 boys with partial androgen insensitivity, 52 with non-specific XY DSD, and 3 with persistent Müllerian duct syndrome. Before starting TRT, liver function and blood count were checked in 19 (68%) and 18 boys (64%), respectively, a bone age assessment was performed in 23 (82%) and bone mineral density assessment in 12 boys (43%). This snapshot of contemporary practice reveals that TRT in boys included in the I-DSD Registry is not very common, whilst the variation in starting and monitoring therapy is quite marked. Standardisation of practice may lead to more effective assessment of treatment outcomes.
AB - It is unclear whether testosterone replacement therapy (TRT) in adolescent boys, affected by a range of endocrine diseases that may be associated with hypogonadism, is particularly common. The aim of this study was to assess the contemporary practice of TRT in boys included in the I-DSD Registry. All participating centres in the I-DSD Registry that had boys between 10 and 18 years of age and with a condition that could be associated with hypogonadism were invited to provide further information in 2019. Information on 162 boys was collected from 15 centres that had a median (range) number of 6 boys per centre (1.35). Of these, 30 (19%) from 9 centres were receiving TRT and the median (range) age at the start was 12.6 years (10.8-16.2), with 6 boys (20%) starting at <12 years. Median (range) age of boys not on TRT was 11.7 years (10.7-17.7), and 69 out of 132 (52%) were <12 years. TRT had been initiated in 20 of 71 (28%) boys with a disorder of gonadal development, 3 of 14 (21%) with a disorder of androgen synthesis, and all 7 (100%) boys with hypogonadotropic hypogonadism. The remainder who did not have TRT included 15 boys with partial androgen insensitivity, 52 with non-specific XY DSD, and 3 with persistent Müllerian duct syndrome. Before starting TRT, liver function and blood count were checked in 19 (68%) and 18 boys (64%), respectively, a bone age assessment was performed in 23 (82%) and bone mineral density assessment in 12 boys (43%). This snapshot of contemporary practice reveals that TRT in boys included in the I-DSD Registry is not very common, whilst the variation in starting and monitoring therapy is quite marked. Standardisation of practice may lead to more effective assessment of treatment outcomes.
KW - Adolescent boys
KW - DSD
KW - Hypogonadism
KW - Testosterone
UR - http://www.scopus.com/inward/record.url?scp=85110085925&partnerID=8YFLogxK
U2 - https://doi.org/10.1159/000516784
DO - https://doi.org/10.1159/000516784
M3 - Article
C2 - 34350903
SN - 1661-5425
VL - 15
SP - 236
EP - 243
JO - Sexual development
JF - Sexual development
IS - 4
ER -